Nutshell Therapeutics (Shanghai) obtained FDA IND clearance for NTS-231, a covalent allosteric molecular glue degrader of NRF2 discovered using its Allostar AI-driven platform. The program centers on covalently binding KEAP1 to promote NRF2 degradation, targeting pathways often implicated in oxidative stress and inflammation. The IND clearance sets the stage for clinical development as the company advances its small-molecule degradation platform.